Skip to main content

Table 4 Pan-cancer Therapy Efficacy model performance assessed using overall survival

From: The impact of pharmacokinetic gene profiles across human cancers

 

Univariate

Multivariate

Rulea

Genomics features

Low-risk (N)

High-risk (N)

High-risk (%)

HR [95% CI]

p-value

HR [95% CI]

p-value

Export

1

2749

109

3.8

1.49 [1.09, 2.05]

1.2 × 10−2

1.49 [1.13, 1.96]

4.7 × 10− 3

Import

1

2777

81

2.8

0.90 [0.61, 1.33]

6.0 × 10−1

1.00 [0.76, 1.32]

1.0 × 100

Metabolism

1

2642

216

7.6

1.26 [0.94, 1.69]

1.3 × 10−1

1.12 [0.85, 1.48]

4.2 × 10− 1

Metabolismb

1

2809

49

1.7

1.74 [1.09, 2.77]

2.1 × 10− 2

1.73 [1.31, 2.28]

9.3 × 10− 5

Target

1

2780

78

2.7

1.12 [0.76, 1.66]

5.6 × 10− 1

1.07 [0.81, 1.41]

6.3 × 10− 1

Any-Hit

3

2530

328

11.5

1.21 [0.94, 1.55]

1.4 × 10− 1

1.17 [0.88, 1.53]

2.8 × 10− 1

Any-PK-Hit

2

2660

198

6.9

1.26 [0.97, 1.64]

7.8 × 10−2

1.27 [0.96, 1.67]

9.4 × 10− 2

Efficacy Model

2

2715

143

5.0

1.41 [1.06, 1.88]

1.9 × 10−2

1.47 [1.11, 1.93]

6.3 × 10− 3

  1. aRules based on tumor-genomic features; see Methods for definitions
  2. bRequiring at least two metabolism genes affected; see Additional file 1: Figure S1 for additional comparisons